Piper Sandler Cuts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.25
Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price target cut by Piper Sandler from $2.00 to $1.25 in a research note released on Thursday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. Several other equities research analysts also recently weighed in on the stock. Stephens reaffirmed an […]
Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price target cut by Piper Sandler from $2.00 to $1.25 in a research note released on Thursday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. Several other equities research analysts also recently weighed in on the stock. Stephens reaffirmed an […]
